Smart Immune — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Smart Immune is a clinical-stage biotech pioneering a next-generation cell therapy platform to address the critical unmet need of delayed immune reconstitution. Its lead program, ProTcell, is an ex vivo generated T-cell progenitor product derived from a patient's own stem cells, designed to rapidly rebuild a complete and functional T-cell repertoire post-transplant. The technology holds promise for improving outcomes in hematopoietic stem cell transplantation (HSCT) for blood cancers and could be applied to treat severe viral infections and primary immunodeficiencies. Backed by venture capital and strategic partnerships, the company is advancing its lead asset into clinical trials.

OncologyInfectious DiseaseImmunology

Technology Platform

ProTcell platform: A proprietary 3D bioreactor system that differentiates a patient's own CD34+ hematopoietic stem cells into early T-cell progenitors (CD7+CD5+ ProTcells) via Notch signaling activation. These progenitors home to the thymus to generate a diverse, functional, and patient-specific T-cell repertoire.

Opportunities

The primary opportunity is to establish a new standard-of-care in hematopoietic stem cell transplantation by dramatically reducing the dangerous period of immune deficiency, thereby lowering mortality, relapse, and costs.

The platform's application could expand to treat immune deficiencies arising from other cancer therapies (like CAR-T) and severe viral infections, creating multiple high-value market segments.

Successful validation could also make the company an attractive partner or acquisition target for large pharma with oncology/immunology portfolios.

Risk Factors

The major risk is clinical failure, where ProTcell fails to demonstrate sufficient safety or efficacy in accelerating functional immune reconstitution in human trials.

Manufacturing complexities and the high cost of goods for an autologous cell therapy pose significant scalability and commercial risks.

The company also faces financing risk as a pre-revenue entity and competition from other therapeutic approaches targeting immune recovery.

Competitive Landscape

Smart Immune competes with companies developing cytokine therapies (e.g., RevImmune's IL-7), thymus tissue engineering (Enzyvant), and other T-cell progenitor or stem cell approaches. Its key differentiation is the direct generation of thymus-homing progenitors designed to produce a fully educated, polyclonal T-cell repertoire. However, it must demonstrate clinical superiority over these alternatives and navigate a space where large pharma is increasingly active in cell therapy.

More companies in Cell & Gene Therapy →More companies in France →